Lymphoma
If it’s your first time on this website, please read the disclaimer section.
May 18 – May 25, 2026
Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial.
JAMA-J AM MED ASSOC · Q1 JOURNAL - RANK #4/332TOP-TIER
This phase 3 randomized trial evaluated tucidinostat plus R-CHOP versus R-CHOP alone in 423 patients with MYC/BCL2 double-expressor lymphoma (DEL), a high-risk DLBCL subtype. Median follow-up was 41.3 months; the combination reduced the risk of progression, relapse, or death by 28% (HR 0.72; 95% CI 0.54-0.96; P=0.02), with 2-year event-free survival of 60.3% vs 50.5%. Complete response rate improved from 61.8% to 73.0% (difference 11.1%; 95% CI 2.3%-20.0%), and toxicity was manageable. This provides a new first-line option for a poor-prognosis DEL population, directly addressing the clinician’s interest in cancer-focused research.
10.1001/jama.2026.4199
May 11 – May 18, 2026
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.
LANCET · Q1 JOURNAL - RANK #1/332TOP-TIER
This phase 3 trial investigated if adding autologous stem-cell transplantation (ASCT) to an ibrutinib-containing regimen improves outcomes in 870 younger mantle cell lymphoma patients. After 54.9 months, ibrutinib-containing groups (with or without ASCT) significantly improved 4-year failure-free survival (81-82% vs 70%) and overall survival (88-90% vs 81%) compared to ASCT alone. However, adding ASCT to ibrutinib offered no supplementary benefit but increased grade 3-5 adverse events (e.g., haematological disorders 54% vs 28%). Therefore, ibrutinib with immunochemotherapy and 2-year ibrutinib maintenance should be considered a new standard of care, potentially sparing patients from ASCT-related toxicity.
10.1016/S0140-6736(26)00362-4
Apr 27 – May 04, 2026
Adult T-Cell Leukemia/Lymphoma and Targeted Maternal Screening.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This population-based study analyzed US cancer registries (2005-2022) to estimate Adult T-cell leukemia/lymphoma (ATLL) incidence. It identified 3228 ATLL cases, finding non-Hispanic Caribbean-born US residents had an incidence rate of 14.1 per million, significantly higher than US/Canada-born populations (0.4 per million; IRR, 32.0), with rates peaking at 33.7 per million. Five-year survival was poor (23.8%), lowest among Caribbean-born individuals, highlighting a critical health disparity for this aggressive cancer. These findings identify early-life HTLV-1 infection as an actionable target for cancer prevention through maternal screening, with implications for reducing future ATLL burden.
10.1001/jamaoncol.2026.0859
Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This randomized, placebo-controlled trial evaluated whether prophylactic B-cell depletion with obinutuzumab could prevent corticosteroid-requiring chronic graft-versus-host disease (cGVHD) in 178 allogeneic transplant recipients. Obinutuzumab significantly reduced the 1-year incidence of steroid-requiring cGVHD to 13.3% compared to 35.2% in the placebo group (p=0.0005) and improved 2-year immunosuppression-free, relapse-free survival (48% vs. 34%). While the study focuses on a post-transplant complication, the findings are highly relevant for clinicians managing hematologic malignancies where cGVHD remains a major barrier to successful recovery. These results suggest that early B-cell depletion is an effective strategy for reducing morbidity and improving long-term outcomes in high-risk cancer patients undergoing transplantation.
10.1200/JCO-25-03104
Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
The TRANSFORM study (NCT03575351) compared lisocabtagene maraleucel (liso-cel) versus standard of care (ASCT) in 136 patients with second-line large B-cell lymphoma (LBCL), utilizing ultrasensitive circulating tumor DNA (ctDNA) to assess disease response. ctDNA clearance predicted longer event-free survival (EFS) in both arms, with significantly more liso-cel-treated patients achieving measurable residual disease (MRD) negativity. Liso-cel demonstrated superior outcomes, including longer EFS and progression-free survival (PFS), compared to ASCT, and ctDNA re-emergence predicted relapse. This research establishes ctDNA-MRD as a valuable prognostic biomarker beyond PET for treatment response and relapse prediction in LBCL, supporting its role in clinical practice.
10.1200/JCO-25-03051
Apr 20 – Apr 27, 2026
Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This expert opinion paper reviews the diagnostic and therapeutic management of various hematologic malignancies diagnosed during pregnancy, addressing the increasing global incidence in this population. The authors evaluate the safety and efficacy of diagnostic modalities and treatment options, including chemotherapy, radiation therapy, and immunotherapy, for conditions such as acute leukemia and lymphomas. It provides clinical guidance on balancing maternal oncological care with fetal safety, emphasizing that more women are now receiving adequate treatment without compromising pregnancy outcomes. The findings suggest that multidisciplinary approaches allow for expanded treatment possibilities, though specific numerical survival data were not provided in this qualitative expert consensus.
10.1200/JCO-25-02351
Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This phase 2 PRIMO trial evaluated the efficacy and safety of duvelisib, an oral dual PI3K-δ/γ inhibitor, in 123 patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Results demonstrated an objective response rate of 48.0% and a complete response rate of 33.3%, with a median overall survival of 12.4 months across the total cohort. Notably, the angioimmunoblastic T-cell lymphoma subgroup showed superior outcomes, including a 62.2% response rate and 18.1-month median overall survival, despite a 74.0% incidence of grade ≥3 adverse events. These findings establish duvelisib as a clinically significant treatment option for aggressive PTCL, particularly for T-follicular helper cell subtypes, warranting further development in oncology practice.
10.1200/JCO-25-03120
Apr 13 – Apr 20, 2026
Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This phase III AUGMENT trial evaluated the long-term efficacy and safety of lenalidomide plus rituximab (R2) compared to rituximab plus placebo in 358 patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL). At a median follow-up of 65.9 months, the R2 group demonstrated significantly improved progression-free survival (HR 0.50; 95% CI, 0.38 to 0.66) and overall survival (HR 0.59; 95% CI, 0.37 to 0.95). Subgroup analyses confirmed these benefits extended to patients with follicular lymphoma, including those aged 70 years and older, with a safety profile consistent with earlier findings. These five-year results solidify the R2 regimen as a standard-of-care treatment option for patients with relapsed/refractory iNHL, offering sustained clinical benefit across age groups.
10.1200/JCO-25-01770
Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders.
NAT REV CLIN ONCOL · Q1 JOURNAL - RANK #2/326TOP-TIER
This review synthesizes emerging evidence on the spectrum, pathobiology, and diagnostic challenges of lymphoproliferative and lymphomatous disorders occurring after CAR T cell therapy for hematological malignancies. The analysis identifies these rare events as including both CAR-transgene-positive and transgene-negative lymphomas, often triggered by factors such as clonal haematopoiesis, viral reactivation, or, in rare instances, vector integration. For clinicians treating cancer, the study provides a framework for recognizing these complex toxicities which differ significantly from traditional chemotherapy side effects and require specific diagnostic evaluation. Improved classification and understanding of these post-therapy malignancies are essential for guiding treatment decisions, enhancing pharmacovigilance, and informing future mechanistic research in cellular immunotherapy.
10.1038/s41571-026-01147-w
Mar 09 – Mar 16, 2026
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study.
LANCET · Q1 JOURNAL - RANK #1/332TOP-TIER
This phase 2, single-arm study (TRANSCEND FL) evaluated the efficacy and safety of lisocabtagene maraleucel, a CD19-directed CAR T-cell therapy, in 66 evaluable patients with relapsed or refractory marginal zone lymphoma (MZL) who had received at least two prior lines of therapy. The primary endpoint was met with a high overall response rate of 95% (95% CI, 87.3–99.1; p<0.0001) over a median follow-up of 24.1 months. Safety results showed manageable toxicity, with grade 3 cytokine release syndrome and neurological events each occurring in only 4% of patients and no grade 4 or 5 events reported. These findings suggest that lisocabtagene maraleucel provides deep and durable responses, establishing it as a viable new treatment option for patients with heavily pretreated MZL.
10.1016/S0140-6736(25)02435-3
Mar 02 – Mar 09, 2026
Outcomes of Older Adults With Advanced Cancer Who Prefer Quality of Life vs Prolonging Survival: A Secondary Analysis of the GAP70+ Cluster Randomized Clinical Trial.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This secondary analysis of the GAP70+ cluster randomized trial evaluated treatment preferences and clinical outcomes among 706 older adults with incurable solid tumors or lymphoma. While 71.7% of patients prioritized quality of life (QoL) over survival (8.4%), no significant differences were found between groups regarding grade 3-5 toxicities (HR 0.84), hospitalizations (HR 0.74), or 1-year survival (HR 1.18). The study directly addresses the clinician’s interest in cancer by examining how patient-centered goals influence the management of advanced malignancies in geriatric populations. These findings suggest that current oncology care delivery may not be sufficiently responsive to individual patient preferences, highlighting a need for better alignment between treatment intensity and patient-defined goals.
10.1001/jamaoncol.2026.0072